<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>mRNA Cancer Vaccines Now Working Against "Untreatable" Pancreatic Tumors | News That's Not Crap</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Nunito:wght@400;500;600;700;800;900&family=Instrument+Serif:ital@0;1&display=swap" rel="stylesheet">
    <style>
        :root {
            --wgac-green: #1B873F;
            --wgac-green-light: #d7f6a4;
            --wgac-blue: #4368ff;
            --wgac-teal: #2dcb98;
            --wgac-coral: #e85d4c;
            --wgac-yellow: #f0c808;
            --wgac-purple: #7b68ee;
            --wgac-pink: #e84393;
            --wgac-brown: #a1512e;
            --white: #ffffff;
            --cream: #faf9f6;
            --dark: #1a1a1a;
            --gray-100: #f5f4f2;
            --gray-200: #e8e6e3;
            --gray-400: #a09d98;
            --gray-600: #6b6761;
            --font-display: 'Nunito', -apple-system, sans-serif;
            --font-body: 'Nunito', -apple-system, sans-serif;
            --font-serif: 'Instrument Serif', Georgia, serif;
            --radius-sm: 0.5rem;
            --radius-md: 1rem;
            --radius-lg: 1.5rem;
            --radius-pill: 100px;
        }

        * { margin: 0; padding: 0; box-sizing: border-box; }

        body {
            font-family: var(--font-body);
            background: var(--cream);
            color: var(--dark);
            line-height: 1.6;
            -webkit-font-smoothing: antialiased;
        }

        a { color: inherit; text-decoration: none; }

        /* Header */
        .site-header {
            position: sticky;
            top: 0;
            z-index: 1000;
        }

        .header-top-bar {
            background: var(--dark);
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 0.5rem 2rem;
        }

        .header-tagline, .header-date {
            font-size: 0.7rem;
            font-weight: 700;
            color: rgba(255,255,255,0.5);
        }

        .header-main {
            background: var(--wgac-blue);
            display: flex;
            align-items: center;
            justify-content: space-between;
            padding: 1rem 2rem;
        }

        .logo {
            display: flex;
            align-items: center;
            gap: 0.5rem;
            text-decoration: none;
        }

        .logo-text {
            font-size: 1.4rem;
            font-weight: 900;
            color: var(--white);
            text-transform: uppercase;
            letter-spacing: -0.03em;
        }

        .crap-box {
            background: var(--white);
            padding: 0.4rem 0.6rem;
            border-radius: 0.3rem;
        }

        .crap-box img {
            height: 1.3rem;
            display: block;
            filter: brightness(0) saturate(100%) invert(29%) sepia(98%) saturate(1654%) hue-rotate(221deg) brightness(101%) contrast(102%);
        }

        .main-nav {
            display: flex;
            gap: 0.35rem;
        }

        .nav-link {
            color: var(--white);
            font-size: 0.7rem;
            font-weight: 800;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            padding: 0.5rem 1rem;
            border-radius: var(--radius-pill);
            background: rgba(255,255,255,0.15);
            transition: all 0.2s ease;
        }

        .nav-link:hover {
            background: rgba(255,255,255,0.3);
        }

        .nav-link.active {
            background: var(--white);
            color: var(--wgac-blue);
        }

        /* Article Hero */
        .article-hero {
            position: relative;
            height: 70vh;
            min-height: 500px;
            max-height: 700px;
            overflow: hidden;
        }

        .article-hero img {
            width: 100%;
            height: 100%;
            object-fit: cover;
        }

        .article-hero-overlay {
            position: absolute;
            inset: 0;
            background: linear-gradient(to top, rgba(0,0,0,0.8) 0%, rgba(0,0,0,0.3) 50%, rgba(0,0,0,0.1) 100%);
        }

        .article-hero-content {
            position: absolute;
            bottom: 0;
            left: 0;
            right: 0;
            padding: 4rem;
            max-width: 900px;
            margin: 0 auto;
            text-align: center;
        }

        .article-tag {
            display: inline-block;
            background: var(--wgac-coral);
            color: white;
            padding: 0.4rem 1rem;
            font-weight: 800;
            font-size: 0.7rem;
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 1.5rem;
            border-radius: var(--radius-pill);
        }

        .article-hero h1 {
            font-family: var(--font-serif);
            font-size: clamp(2.5rem, 5vw, 3.5rem);
            font-weight: 400;
            line-height: 1.15;
            color: white;
            margin-bottom: 1.5rem;
        }

        .article-meta {
            color: rgba(255,255,255,0.7);
            font-size: 0.9rem;
            font-weight: 600;
        }

        .article-meta span { margin: 0 0.75rem; }

        /* Article Content */
        .article-content {
            max-width: 700px;
            margin: 0 auto;
            padding: 4rem 2rem;
        }

        .article-lead {
            font-size: 1.35rem;
            line-height: 1.7;
            color: var(--dark);
            margin-bottom: 2rem;
            font-weight: 500;
        }

        .article-body p {
            font-size: 1.1rem;
            line-height: 1.8;
            margin-bottom: 1.5rem;
            color: var(--gray-600);
        }

        .article-body h2 {
            font-family: var(--font-display);
            font-size: 1.75rem;
            font-weight: 900;
            margin: 3rem 0 1.5rem;
            color: var(--dark);
        }

        .article-body blockquote {
            border-left: 4px solid var(--wgac-coral);
            padding-left: 1.5rem;
            margin: 2rem 0;
            font-family: var(--font-serif);
            font-size: 1.4rem;
            font-style: italic;
            color: var(--dark);
            border-radius: 0 var(--radius-sm) var(--radius-sm) 0;
        }

        /* Stats Box */
        .stats-box {
            background: var(--wgac-coral);
            color: white;
            padding: 2.5rem;
            margin: 3rem 0;
            border-radius: var(--radius-lg);
        }

        .stats-box h3 {
            font-family: var(--font-display);
            font-size: 1.25rem;
            font-weight: 800;
            margin-bottom: 1.5rem;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 2rem;
        }

        .stat-item { text-align: center; }

        .stat-number {
            font-family: var(--font-display);
            font-size: 3rem;
            font-weight: 900;
            line-height: 1;
            margin-bottom: 0.5rem;
        }

        .stat-label {
            font-size: 0.8rem;
            font-weight: 600;
            opacity: 0.9;
        }

        /* Image with caption */
        .article-figure {
            margin: 3rem -4rem;
        }

        .article-figure img {
            width: 100%;
            display: block;
            border-radius: var(--radius-md);
        }

        .article-figure figcaption {
            font-size: 0.85rem;
            color: var(--gray-400);
            padding: 1rem 4rem;
            text-align: center;
        }

        .sources-box {
            margin-top: 3rem;
            padding: 2rem;
            background: var(--gray-100);
            border-left: 4px solid var(--wgac-coral);
            border-radius: 0 var(--radius-md) var(--radius-md) 0;
        }

        .sources-box h3 {
            font-family: var(--font-body);
            font-size: 0.8rem;
            font-weight: 800;
            text-transform: uppercase;
            letter-spacing: 1px;
            color: var(--gray-600);
            margin-bottom: 1rem;
        }

        .sources-box ul {
            list-style: none;
        }

        .sources-box li {
            margin-bottom: 0.5rem;
        }

        .sources-box a {
            color: var(--wgac-coral);
            font-size: 0.9rem;
            font-weight: 600;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: border-color 0.2s ease;
        }

        .sources-box a:hover {
            border-bottom-color: var(--wgac-coral);
        }

        /* Related Articles */
        .related-section {
            background: var(--gray-100);
            padding: 4rem 2rem;
            margin-top: 4rem;
        }

        .related-inner {
            max-width: 1200px;
            margin: 0 auto;
        }

        .related-title {
            font-family: var(--font-display);
            font-size: 1.5rem;
            font-weight: 900;
            margin-bottom: 2rem;
            padding-bottom: 1rem;
            border-bottom: 3px solid var(--dark);
        }

        .related-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 1.5rem;
        }

        .related-card {
            background: white;
            border-radius: var(--radius-lg);
            overflow: hidden;
            cursor: pointer;
            transition: transform 0.2s ease, box-shadow 0.2s ease;
        }

        .related-card:hover {
            transform: translateY(-4px);
            box-shadow: 0 8px 30px rgba(0,0,0,0.1);
        }

        .related-card:hover h4 { color: var(--wgac-blue); }

        .related-card img {
            width: 100%;
            height: 180px;
            object-fit: cover;
            display: block;
        }

        .related-card-content {
            padding: 1.25rem;
        }

        .related-card h4 {
            font-family: var(--font-display);
            font-size: 1.1rem;
            font-weight: 800;
            line-height: 1.35;
            transition: color 0.2s ease;
        }

        /* Footer */
        .site-footer {
            background: var(--dark);
            color: var(--white);
            padding: 4rem 2rem;
        }

        .footer-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: flex-start;
        }

        .footer-brand {
            max-width: 320px;
        }

        .footer-logo {
            display: flex;
            align-items: center;
            gap: 0.4rem;
            margin-bottom: 1rem;
        }

        .footer-logo .logo-text {
            font-size: 1rem;
            font-weight: 900;
            color: var(--white);
            text-transform: uppercase;
            letter-spacing: -0.03em;
        }

        .footer-logo .crap-box {
            background: var(--white);
            padding: 0.3rem 0.5rem;
            border-radius: 0.25rem;
        }

        .footer-logo .crap-box img {
            height: 0.9rem;
            filter: brightness(0) saturate(100%) invert(29%) sepia(98%) saturate(1654%) hue-rotate(221deg) brightness(101%) contrast(102%);
        }

        .footer-tagline {
            font-size: 0.9rem;
            color: var(--gray-400);
        }

        .footer-nav {
            display: flex;
            gap: 4rem;
        }

        .footer-col h4 {
            font-size: 0.7rem;
            font-weight: 800;
            letter-spacing: 1px;
            text-transform: uppercase;
            color: var(--gray-400);
            margin-bottom: 1rem;
        }

        .footer-col ul {
            list-style: none;
        }

        .footer-col li {
            margin-bottom: 0.5rem;
        }

        .footer-col a {
            font-size: 0.9rem;
            color: var(--white);
            opacity: 0.7;
            transition: opacity 0.2s;
        }

        .footer-col a:hover {
            opacity: 1;
        }

        .footer-attribution {
            max-width: 1400px;
            margin: 2rem auto 0;
            text-align: center;
            font-size: 0.85rem;
            color: var(--gray-400);
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 0.75rem;
        }

        .wgac-footer-logo {
            height: 1.5rem;
            filter: brightness(0) invert(1);
            opacity: 0.7;
            transition: opacity 0.2s;
        }

        .wgac-footer-logo:hover {
            opacity: 1;
        }

        /* Responsive */
        @media (max-width: 1024px) {
            .related-grid {
                grid-template-columns: 1fr;
            }
            .footer-content {
                flex-direction: column;
                gap: 3rem;
            }
        }

        @media (max-width: 768px) {
            .header-top-bar { padding: 0.5rem 1rem; }
            .header-main { padding: 1rem; flex-direction: column; gap: 1rem; }
            .main-nav { flex-wrap: wrap; justify-content: center; }
            .article-hero-content { padding: 2rem 1.5rem; }
            .article-content { padding: 2rem 1.5rem; }
            .article-figure { margin: 2rem -1.5rem; }
            .article-figure img { border-radius: 0; }
            .article-figure figcaption { padding: 1rem 1.5rem; }
            .stats-grid { grid-template-columns: 1fr; gap: 1.5rem; }
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header class="site-header">
        <div class="header-top-bar">
            <span class="header-tagline">The antidote to doom-scrolling</span>
            <span class="header-date">January 29, 2026</span>
        </div>
        <div class="header-main">
            <a href="../index.html" class="logo">
                <span class="logo-text">News That's Not</span>
                <div class="crap-box"><img src="../crap-logo-white.png" alt="crap"></div>
            </a>
            <nav class="main-nav">
                <a href="../index.html" class="nav-link">Today</a>
                <a href="../climate.html" class="nav-link">Climate</a>
                <a href="../health.html" class="nav-link active">Health</a>
                <a href="../science.html" class="nav-link">Science</a>
                <a href="../people.html" class="nav-link">People</a>
                <a href="../wildlife.html" class="nav-link">Wildlife</a>
                <a href="../cats.html" class="nav-link">Cats</a>
            </nav>
        </div>
    </header>

    <!-- Article Hero -->
    <div class="article-hero">
        <img src="https://images.unsplash.com/photo-1631549916768-4119b2e5f926?w=1920&q=80" alt="Cancer research laboratory">
        <div class="article-hero-overlay"></div>
        <div class="article-hero-content">
            <span class="article-tag">Health</span>
            <h1>mRNA Cancer Vaccines Now Working Against "Untreatable" Pancreatic Tumors</h1>
            <div class="article-meta">
                <span>By Dr. Helix Strand</span>
                <span>·</span>
                <span>January 29, 2026</span>
                <span>·</span>
                <span>6 min read</span>
            </div>
        </div>
    </div>

    <!-- Article Content -->
    <article class="article-content">
        <p class="article-lead">
            Pancreatic cancer is notorious for two things: it's almost always fatal, and it laughs at chemotherapy. But a personalized mRNA vaccine approach—the same technology behind COVID shots—is showing results that oncologists are calling "unprecedented," with immune responses persisting for nearly four years.
        </p>

        <div class="article-body">
            <p>
                Let's be blunt about pancreatic cancer: it's a nightmare. By the time it's diagnosed, it's usually too late. The five-year survival rate hovers around 12%. It kills 50,000 Americans every year. Oncologists, in private moments, will tell you it's the cancer they fear most.
            </p>

            <p>
                So when researchers at Memorial Sloan Kettering Cancer Center announced that an experimental mRNA vaccine called autogene cevumeran had shown sustained immune activity in pancreatic cancer patients for nearly four years, the oncology community paid very close attention.
            </p>

            <blockquote>
                "We've been trying to teach the immune system to fight pancreatic cancer for decades. mRNA finally gave us the vocabulary."
            </blockquote>

            <p>
                The treatment involves sequencing each patient's tumor to identify up to 20 unique mutations (neoantigens), then constructing a personalized mRNA vaccine that teaches the immune system to recognize and attack those specific cancer signatures. Patients receive the vaccine alongside atezolizumab (an immune checkpoint inhibitor) followed by chemotherapy.
            </p>

            <div class="stats-box">
                <h3>The Trial Results</h3>
                <div class="stats-grid">
                    <div class="stat-item">
                        <div class="stat-number">50%</div>
                        <div class="stat-label">Patients with vaccine response</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">4</div>
                        <div class="stat-label">Years of sustained immune activity</div>
                    </div>
                    <div class="stat-item">
                        <div class="stat-number">20</div>
                        <div class="stat-label">Target neoantigens per vaccine</div>
                    </div>
                </div>
            </div>

            <h2>How mRNA Cancer Vaccines Work</h2>

            <p>
                The approach is elegant, if somewhat mind-bending. First, surgeons remove a patient's tumor and sequence its DNA, identifying mutations unique to that specific cancer. Then, BioNTech constructs mRNAs for up to 20 target neoantigens—mutations that produce abnormal proteins the immune system can learn to recognize.
            </p>

            <p>
                The result is a personalized vaccine that's essentially a wanted poster for your specific cancer. Your immune system, finally given the information it needs, starts hunting.
            </p>

            <p>
                "Every cancer is different," explains the MSK research team. "Even two pancreatic cancers in two different patients will have different mutations. That's why one-size-fits-all approaches kept failing. mRNA lets us create a custom weapon for each patient."
            </p>

            <figure class="article-figure">
                <img src="https://images.unsplash.com/photo-1579165466741-7f35e4755183?w=1400&q=80" alt="mRNA vaccine production">
                <figcaption>mRNA technology, proven effective against COVID-19, is now being adapted for cancer treatment. Photo: BioNTech</figcaption>
            </figure>

            <h2>The Results So Far</h2>

            <p>
                After a year and a half, 50% of vaccinated patients showed cells with evidence of the vaccine response, and these individuals also had delayed recurrence of their cancer. The remarkable finding: after three years, the vaccine responders had not reached a measurement for recurrence-free survival—because most of them were doing well.
            </p>

            <p>
                The immune responses have now persisted for nearly four years in some patients, showing a reduced risk of cancer recurrence compared to non-responders. In pancreatic cancer, where recurrence is almost inevitable, that's extraordinary.
            </p>

            <p>
                A larger Phase 2 trial, sponsored by Genentech in collaboration with BioNTech, began in July 2023 and will enroll approximately 260 patients at sites around the world. Data from these key trials is expected in late 2025 or early 2026.
            </p>

            <h2>What This Means for Other Cancers</h2>

            <p>
                Pancreatic cancer was chosen precisely because it's so difficult. If mRNA vaccines work here, they could work almost anywhere. BioNTech is already running trials for melanoma, colon cancer, and lung cancer.
            </p>

            <p>
                In melanoma, Moderna and Merck's mRNA-4157 (V940) combined with pembrolizumab reduced post-resection recurrence by 44% and distant metastasis risk by 65% compared to anti-PD-1 therapy alone. Three-year follow-up data shows sustained clinical benefit, with recurrence-free survival rates maintaining superiority over pembrolizumab monotherapy.
            </p>

            <p>
                The continued success has catalyzed the global expansion of Phase 3 trials, with regulatory submissions anticipated in 2026 and first commercial approvals expected by late 2026 to 2027.
            </p>

            <h2>The Road Ahead</h2>

            <p>
                With over 60 RNA cancer vaccine treatments currently in development, this represents a major shift in personalized cancer care. Personalized vaccines may command premium prices—an estimated $100,000-$300,000 per patient—but cost-effectiveness could be justified in settings where relapse risk is high.
            </p>

            <p>
                For patients with pancreatic cancer, the timeline matters. The technology that seemed like science fiction a decade ago is now showing real results in real patients who are still alive years after treatment.
            </p>

            <p>
                "We're not talking about a cure yet," the MSK team cautions. "But we're talking about buying time—maybe a lot of time—for patients who previously had none."
            </p>

            <div class="sources-box">
                <h3>Sources</h3>
                <ul>
                    <li><a href="https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out" target="_blank">Memorial Sloan Kettering: mRNA Vaccine Pancreatic Cancer Trial</a></li>
                    <li><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2025/neoantigen-vaccine-pancreatic-kidney-cancer" target="_blank">National Cancer Institute: Neoantigen Vaccines for Pancreatic Cancer</a></li>
                    <li><a href="https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html" target="_blank">BioNTech: Pipeline and Products</a></li>
                    <li><a href="https://cromospharma.com/cancer-vaccines-2025-part-i-the-mrna-revolution/" target="_blank">Cancer Vaccines 2025: The Rise of mRNA Therapies</a></li>
                </ul>
            </div>
        </div>
    </article>

    <!-- Related Articles -->
    <section class="related-section">
        <div class="related-inner">
            <h2 class="related-title">More Health Stories</h2>
            <div class="related-grid">
                <a href="huntingtons-gene-therapy.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1532094349884-543bc11b234d?w=600&q=80" alt="Laboratory">
                    <div class="related-card-content">
                        <h4>Gene Therapy Just Crushed Huntington's Disease By 75%</h4>
                    </div>
                </a>
                <a href="blindness-treatment.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=600&q=80" alt="Medical research">
                    <div class="related-card-content">
                        <h4>"Untreatable" Blindness Just Got Treated</h4>
                    </div>
                </a>
                <a href="crispr-baby.html" class="related-card">
                    <img src="https://images.unsplash.com/photo-1530026405186-ed1f139313f8?w=600&q=80" alt="Baby">
                    <div class="related-card-content">
                        <h4>CRISPR-Edited Baby KJ Is Now Walking and Thriving</h4>
                    </div>
                </a>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="site-footer">
        <div class="footer-content">
            <div class="footer-brand">
                <div class="footer-logo">
                    <span class="logo-text">News That's Not</span>
                    <div class="crap-box"><img src="../crap-logo-white.png" alt="crap"></div>
                </div>
                <p class="footer-tagline">The antidote to doom scrolling.</p>
            </div>
            <nav class="footer-nav">
                <div class="footer-col">
                    <h4>Sections</h4>
                    <ul>
                        <li><a href="../climate.html">Climate</a></li>
                        <li><a href="../health.html">Health</a></li>
                        <li><a href="../science.html">Science</a></li>
                        <li><a href="../people.html">People</a></li>
                        <li><a href="../wildlife.html">Wildlife</a></li>
                        <li><a href="../cats.html">Cats</a></li>
                    </ul>
                </div>
                <div class="footer-col">
                    <h4>About</h4>
                    <ul>
                        <li><a href="../mission.html">Our Mission</a></li>
                        <li><a href="../team.html">Team</a></li>
                        <li><a href="../contact.html">Contact</a></li>
                    </ul>
                </div>
            </nav>
        </div>
        <div class="footer-attribution">
            <span>Proudly produced by the very handsome people at</span>
            <a href="https://whogivesacrap.org" target="_blank">
                <img src="../WGAC-Logo-White.png" alt="Who Gives A Crap" class="wgac-footer-logo">
            </a>
        </div>
    </footer>
</body>
</html>
